Is there a rationale in combining anticonvulsants for bipolar patients?;Rationale für eine kombinationstherapie von antikonvulsiva bei bipolaren störungen

Neuropsychiatrie

Volumn 21, Issue 2, 2007, Pages 159-171

  Conca, Andreas ^a,b,e   Grohmann, Renate ^c   Di Pauli, Jan ^a,b   Hausmann, Armand ^a,d  

^a AG der ÖGPP für Spezielle Biologische Verfahren in der Psychiatrie   (Austria)

^b Landeskrankenhaus Rankweil   (Austria)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^e Landeskrankenhaus Rankweil   (Austria)

Author keywords

Anticonvulsants; Bipolar disorder; Combination drug therapy; Mood stabilizer

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NORTRIPTYLINE; OXCARBAZEPINE; PERPHENAZINE; TIAGABINE; TRANQUILIZER; VALPROIC ACID;

ARTICLE; BIPOLAR DISORDER; CLINICAL FEATURE; COMORBIDITY; DISEASE SEVERITY; HUMAN; INCIDENCE; TREATMENT INDICATION;

ACUTE DISEASE; ANTICONVULSANTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CHRONIC DISEASE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE;

EID: 34447249748     PISSN: 09486259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Amann B., Grunze H.: Neurochemical underpinnings in bipolar disorder and epilepsy. Epilepsia 46, 26-30 (2005).
2. American Psychiatric Association.: Practice guideline for the treatment of patients with bipolar disorder (revision). Copyright 2002, American Psychiatric Association.
3. Baethge C., Baldessarini R.J., Mathiske-Schmidt K., Hennen J., Berghofer A., Muller-Oerlinghausen B., Bschor T., Adli M., Bauer M.: Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry 66, 174-182 (2005).
4. Bauer M.S., Mitchner L.: What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 161, 3-18 (2004).
5. Bauer M.S., Altshuler L., Evans D.R., Beresford T., Williford W.O., Hauger R., V.A.: Cooperative Study #430 Team Prevalence and distinct correlates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. J Affect Disord 85, 301-315 (2005).
6. Book S.W., Myrick H.: Novel anticonvulsants in the treatment of alcoholism. Expert Opin Investig Drugs 14, 371-376 (2005).
7. Braunig P., Kruger S.: Levetiracetam in the treatment of rapid cycling bipolar disorder. J Psychopharmacol 17, 239-41 (2003).
8. Breese G.R., Overstreet D.H., Knapp D.J.: Conceptual framework for the etiology of alcoholism: a "kindling"/stress hypothesis. Psychopharmacology 178, 367-380 (2005).
9. Denicoff K.D., Smith-Jackson E.E., Disney E.R., Ali S.O., Leverich G.S., Post R.M.: Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 58, 470 478 (1997a).
10. Denicoff K.D., Smith-Jackson E.E., Bryan A.L., Ali S.O., Post R.M.: Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 154, 1456 1458 (1997b).
11. Evins A.E.: Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry 64, 9-14 (2003).
12. File S.E., Wilks L.J.: Effects of sodium phenobarbital on motor activity and exploration in the mouse: development of tolerance and incidence of withdrawal responses. Pharmacol Biochem Behav 35, 317-320 (1990).
13. Frye M.A., Ketter T.A., Leverich G.S., Huggins T., Lantz C., Denicoff K.D., Post R.M.: The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61, 9-15 (2000).
14. Gajwani P., Forsthoff A., Muzina D., Amann B., Gao K., Elhaj O., Calabrese J.R., Grunze H.: Antiepileptic drugs in mood-disordered patients. Epilepsia 46, 38-44 (2005).
15. Goldberg J.F., Burdick K.E.: Cognitive side effects of anticonvulsants. J Clin Psychiatry 62, 27-33 (2001).
16. Goldberg J.F., Truman C.J.: Antidepressant-induced mania: an overview of current controversies. Bipolar Disord 5, 407-420 (2003)
17. Goodwin F.K.: Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J Clin Psychiatry 64, 18-24 (2003).
18. Goodwin G.M.: Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17, 149-173 (2003).
19. Grohmann R., Engel R.R., Ruther E., Hippius H.: The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37, 4-11 (2004).
20. Grunze H., Kasper S., Goodwin G., Bowden C., Baldwin D., Licht R., Vieta E., Moller H.J.: World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Bipolar Disorders.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry 3, 115-24 (2002).
21. Grunze H., Kasper S., Goodwin G., Bowden C., Baldwin D., Licht R.W., Vieta E., Moller H.J.: WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry 4, 5-13 (2003).
22. Grunze H., Kasper S., Goodwin G., Bowden C., Moller H.J.: WFSBP Task Force on Treatment Guidelines for Bipolar Disorders.The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 5, 120-35 (2004).
23. Hausmann A., Weiss U., Strauss R., Conca A.: Sind Antispychotika Phasenprophylaktika? Psychiatrie und Psychotherapie 1-2, 77-91 (2005).
24. Hemminki E.: Polypharmacy among psychiatric patients. Acta Psychiatr Scand 56, 347-356 (1977).
25. Inoue K., Arima S., Tanaka K., Fukui Y., Kato N.: A lithium and carbamazepine combination in the treatment of bipolar disorder-a preliminary report. Folia Psychiatr Neurol Jpn 35, 465-475 (1981).
26. Kasper S., Haushofer M., Zapotoczky H.G., Aschauer H., Wolf R., Hinterhuber H., Bonelli M., Wuschitz A.: Konsensus-Statement: Diagnostik und Therapie der bipolaren Störungen. Neuropsychiatrie 13, 100-108 (1999).
27. Kessing L.V., Hansen M.G., Andersen P.K., Angst J.: The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders - a life-long perspective. Acta Psychiatr Scand. 109, 339-344 (2004).
28. Kupfer D.J., Frank E., Grochocinski V.J., Cluss P.A., Houck P.R., Stapf D.A.: Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 63, 120-125 (2002).
29. Lykouras L., Hatzimanolis J.: Adjunctive topiramate in the maintenance treatment of bipolar disorders: an open-label study. Curr Med Res Opin 20, 843-847 (2004).
30. Lira P.Z., Tunis S.L., Edell W.S., Jensik S.E., Tohen M.: Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disord 3, 165-173 (2001).
31. Loscher W.: Mechanisms of drug resistance. Epileptic Disord 7, 3-9 (2005).
32. Luszczki J.J., Czuczwar M., Kis J., Krysa J., Pasztelan I., Swiader M., Czuczwar S.J.: Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44, 1003-1013 (2003).
33. Luszczki J.J., Czuczwar S.J.: Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia 45, 895-907 (2004).
34. Luszczki J.J., Andres M.M., Czuczwar P., Cioczek-Czuczwar A., Wojcik-Cwikla J., Ratnaraj N., Patsalos P.N., Czuczwar S.J.: Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice. Eur Neuropsychopharmacol 15, 609-616 (2005).
35. Maj M., Pirozzi R., Magliano L., Bartoli L.: The prognostic significance of "switching" in patients with bipolar disorder: a 10-year prospective follow-up study. Am J Psychiatry 159, 1711-1717 (2002).
36. Malhi G.S., Mitchell P.B., Salim S.: Bipolar depression: management options. CNS Drugs 17, 9-25 (2003).
37. McIntyre R.S., Konarski J.Z., Yatham L.N.: Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol 19, 369-386 (2004).
38. Mulsant B.H., Alexopoulos G.S., Reynolds C.F. 3rd, Katz I.R., Abrams R., Oslin D., Schulberg H.C: PROSPECT Study Group. Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm. Int J Geriatr Psychiatry 16, 585-592 (2001).
39. Nonaka S., Katsube N., Chuang D.M.: Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. J Pharmacol Exp Ther 286, 539-547 (1998).
40. Pachet A.K., Wisniewski A.M.: The effects of lithium on cognition: an updated review. Psychopharmacology 170, 225-234 (2003).
41. Pande A.C., Davidson J.R., Jefferson J.W., Janney C.A., Katzelnick D.J., Weisler R.H., Greist J.H., Sutherland S.M.: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19, 341-348 (1999).
42. Pande A.C., Crockatt J.G., Janney C.A., Werth J.L., Tsaroucha G.: Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2, 249 255 (2000a).
43. Pande A.C., Pollack M.H., Crockatt J., Greiner M., Chouinard G., Lydiard R.B., Taylor C.B., Dager S.R., Shiovitz T.:Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20, 467-471 (2000b).
44. Perucca E.: Overtreatment in epilepsy: adverse consequences and mechanisms. Epilepsy Res 52, 25-33 (2002).
45. Pies R.: Combining lithium and anticonvulsants in bipolar disorder: a review. Ann Clin Psychiatry 14, 223-232 (2002).
46. Post R.M., Leverich G.S., Denicoff K.D., Frye M.A., Kimbrell T.A., Dunn R.: Alternative approaches to refractory depression in bipolar illness. Depress Anxiety 5, 175-189 (1997).
47. Post R.M., Leverich G.S., Altshuler L.L., Frye M.A., Suppes T.M., Keck P.E. Jr., McElroy S.L., Kupka R., Nolen W.A., Grunze H., Walden J.: An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord 5, 310-319 (2003a).
48. Post R.M., Denicoff K.D., Leverich G.S., Altshuler L.L., Frye M.A., Suppes T.M., Rush A.J., Keck P.E. Jr., McElroy S.L., Luckenbaugh D.A., Pollio C., Kupka R., Nolen W.A.: Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 64, 680-690 (2003b).
49. Post R.M., Altshuler L.L., Frye M.A., Suppes T., McElroy S.L., Keck P.E. Jr., Leverich G.S., Kupka R., Nolen W.A., Luckenbaugh D.A., Walden J., Grunze H.: Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry 66, 370-374 (2005).
50. Reijs R., Aldenkamp A.P., De Krom M.: Mood effects of antiepileptic drugs. Epilepsy Behav 5, 66-76 (2004).
51. Rickels K., Pollack M.H., Feltner D.E., Lydiard R.B., Zimbroff D.L., Bielski R.J., Tobias K., Brock J.D., Zornberg G.L., Pande A.C.: Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62, 1022-30 (2005).
52. Rittmannsberger H.: The use of drug monotherapy in psychiatric inpatient treatment. Prog Neuropsychopharmacol Biol Psychiatry 26, 547-551 (2002).
53. Rittmannsberger H.: Polypharmacy in psychiatric inpatient treatment. Am J Psychiatry 161, 761 (2004).
54. Rogawski M.A., Loscher W.: The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10, 685-692 (2004).
55. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 38, 280-305 (2004).
56. Sachs G.S.: Decision tree for the treatment of bipolar disorder. J Clin Psychiatry 64, 35-40 (2003).
57. Salloum I.M., Cornelius J.R., Daley D.C., Kirisci L., Himmelhoch J.M., Thase M.E.: Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 62, 37-45 (2005).
58. Sills G.J., Butler E., Thompson G.G., Brodie M.J.: Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. Seizure 13, 287-95 (2004).
59. Simon N.M., Otto M.W., Wisniewski S.R., Fossey M., Sagduyu K., Frank E., Sachs G.S., Nierenberg A.A., Thase M.E., Pollack M.H.: Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 161, 222-229 (2004).
60. Solomon D.A., Ryan C.E., Keitner G.I., Miller I.W., Shea M.T., Kazim A., Keller M.B.: A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar 1 disorder. J Clin Psychiatry 58,95 99 (1997).
61. Sun M., van Rijn C.M., Liu Y., Wang M.: Combination of carbamazepine and valproate in different dose proportions in maximal electroshock seizure model in mice. Epilepsy Res 51, 5-11 (2002).
62. Xamayo J., Zarate C., Vieta E., Tohen M.: Medications for bipolar disorders: a review of their therapeutic and pharmacological differences. Part II: from sinapse to genes. Actas Esp Psiquiatr 32, 18-37 (2004).
63. Turnheim K.: Drug interactions with antiepileptic agents. Wien Klin Wochenschr 116, 112-118 (2004).
64. Van Gorp W.G., Altschuler L., Theberge D.C., Wilkins J., Dixon W.: Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. Arch Gen Psychiatry 55, 41-46 (1998).
65. Vestergaard P.: Guidelines for maintenance treatment of bipolar disorder: are there discrepancies between European and North American recommendations? Bipolar Disord 6, 519-522 (2004).
66. Vieta E., Goikolea J.M., Olivares J.M., Gonzalez-Pinto A., Rodriguez A., Colom F., Comes M., Torrent C., Sanchez-Moreno J.: 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. J Clin Psychiatry 64, 834-839 (2003a).
67. Vieta E., Sanchez-Moreno J., Goikolea J.M., Torrent C., Benabarre A., Colom F., Martinez-Aran A., Reinares M., Comes M., Corbella B.: Adjunctive topiramate in bipolar II disorder. World J Biol Psychiatry 4, 172-176 (2003b).
68. Viola R., Csukonyi K., Doro P., Janka Z., Soos G.: Reasons for polypharmacy among psychiatric patients. Pharm World Sci 26, 143-147 (2004).
69. White J.R., Walczak T.S., Leppik I.E., Rarick J., Tran T., Beniak T.E., Matchinsky D.J., Gumnit R.J.: Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 61, 1218-1221 (2003).
70. Young L.T., Joffe R.T., Robb J.C., MacQueen G.M., Marriott M., PatelisSiotis I.: Double-blind comparison of addition of a second mood-stabilizer versus an antidepressant to an initial mood-stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 157, 124 126 (2000).
71. Zarate C.A. Jr., Quiroz J.A.: Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord 5, 217-225 (2003).
72. Zhang Z.J., Russell S., Obeng K, Postma T., Obrocea G., Weiss S.R., Post R.M.: Coadministration of gabapentin or MK-801 with lamotrigine slows tolerance to its anticonvulsant effects on kindled seizures. Pharmacol Biochem Behav 74, 565-571 (2003a).
73. Zhang Z.J., Xing G.Q., Russell S., Obeng K., Post R.M.: Unidirectional cross-tolerance from levetiracetam to carbamazepine in amygdala-kindled seizures. Epilepsia 44, 1487-1493 (2003b).